Watch BDPT. Know when insiders buy.
One email the day a filing lands. Free.
BDPT
BIOADAPTIVES, INC.
0.00
+0.00 +3.64%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $224KP/E —DIV YIELD —FCF YIELD —REV TTM $26K +694.1%NET INCOME −$1.2MNET CASH —52W 0.00 – 0.06SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $5K | +55.0% | 85.0% | −$197K | $150K | — | 0.00 | −$44K | — | — | Aug 19 |
| Q1 2026 · Mar 31 | $6K | — | 74.6% | −$198K | −$111K | — | -0.01 | −$85K | — | — | Aug 19 |
| Q4 2025 · Dec 31derived | $10K | — | 72.7% | −$248K | −$823K | — | -0.07 | −$156K | $0 | −$156K | Apr 14 |
| Q3 2025 · Sep 30 | $5K | — | 83.1% | −$266K | −$380K | — | -0.04 | −$151K | $0 | −$151K | Nov 14 |
| Q2 2025 · Jun 30 | $3K | +376.9% | 33.0% | −$279K | −$158K | — | -0.02 | −$111K | — | — | Aug 19 |
| Q1 2025 · Mar 31 | $0 | −100.0% | — | −$249K | −$197K | — | -0.02 | −$98K | — | — | Aug 19 |
| Q4 2024 · Dec 31derived | $0 | −100.0% | — | −$337K | −$372K | — | -0.04 | −$101K | $0 | −$101K | Apr 14 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$122K | −$38K | — | 0.00 | −$56K | $0 | −$56K | Nov 14 |
| Q2 2024 · Jun 30 | $675 | — | 63.6% | −$93K | −$183K | — | 0.06 | −$51K | — | — | Nov 14 |
| Q1 2024 · Mar 31 | $12K | — | 30.0% | −$50K | −$307K | — | -0.04 | −$41K | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | $7K | — | 37.5% | −$62K | −$268K | — | -0.12 | −$91K | — | — | Apr 15 |
| Q3 2023 · Sep 30 | $16K | — | 29.7% | −$92K | −$13K | — | 0.00 | −$56K | — | — | Nov 19 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $18K | 68.4% | −$1M | −$1.6M | -8523.4% | -0.15 | −$516K | $18K | −$534K | — | — |
| FY2024 · to Dec 31 | $13K | 31.8% | −$602K | −$899K | -7097.3% | -0.11 | −$250K | $0 | −$250K | — | — |
| FY2023 · to Dec 31 | $29K | 37.9% | −$229K | −$712K | -2494.2% | -0.12 | −$224K | — | — | — | — |
| FY2022 · to Dec 31 | $17K | 41.5% | −$422K | −$896K | -5214.1% | — | −$227K | — | — | — | — |
| FY2021 · to Dec 31 | $20K | 51.1% | — | −$1M | -5309.2% | — | −$159K | — | — | — | — |
| FY2020 · to Dec 31 | $16K | 37.3% | — | −$847K | -5189.2% | -0.04 | −$107K | — | — | — | — |
Every number comes from BIOADAPTIVES, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.